Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + Regorafenib in Advanced Colorectal Cancer
NCT03946917Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2019
- Primary completion
- May 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in colorectal cancer (CRC), sponsored by Sun Yat-sen University. Primary endpoints: Maximum Tolerated Dose at 28 days, Dose Limiting Toxicity at 28 days and 1 more. Status: unknown.
02
Drugs
toripalimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03946917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03946917.